What podcasts say about AbbVie
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about AbbVie
14 statements · 12 positive · 2 negative
AbbVie has delivered twice the market return with one-third the market risk.
“You're getting twice the market return for one-third of the market risk.”
Open the episode · AI Relief Rally, Nvidia Governance and CoreWeave EarningsListen at 30:46
Investors should wait to buy AbbVie at a lower price.
“I would just love to buy it cheaper.”
Open the episode · Tech Tumbles In Market Sell-Off… And Moderna’s Meltdown After Data Leak 10/22/26Listen at 31:28
Aldeyra’s potential AbbVie partnership would have approximately 60–40 economics.
“it would also allow them to go into a partnership where it's pretty much 60-40 AbbVie.”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 15:09
AbbVie offers a 2.5% dividend and double-digit growth rate
“We like the 2.5% dividend. We like the double-digit growth rate.”
Open the episode · AI debt Fears Fuel Tech Volatility: The Investment Committee's Strategy 10/16/26Listen at 28:37
The committee initiated AbbVie at 1% and plans to increase it to 5% on weakness
“we initiated a 1%. position. We ultimately want to get it up to 5% on any pullbacks and any weakness will add to it.”
Open the episode · AI debt Fears Fuel Tech Volatility: The Investment Committee's Strategy 10/16/26Listen at 28:56
AbbVie’s diversification beyond immunology is favorable long term
“they are expanding outside of the immunology space, which I think is a creative for them long term.”
Open the episode · The State of the AI Trade 10/9/26Listen at 41:11
AbbVie’s technical and growth profile looks favorable.
“AbbVie looks pretty good.”
Open the episode · Stocks Pare Losses As Yields Slash Gains; AbbVie, Apple, Micron In FocusListen at 15:34
AbbVie’s acquired Cerevel product is currently used for Parkinson’s disease.
“That product is being used now in Parkinson's.”
Open the episode · Strong Dollar Keeps Climbing… And The Outlook For The Pharma Trade 10/5/26Listen at 29:37
Litowitz made a large bet that the AbbVie-Shire merger would be approved.
“we had a very large bet that the deal would go through.”
Open the episode · E417: $20B Investor on Risk, Uncertainty & AdaptabilityListen at 6:05
The AbbVie-Shire tax-policy uncertainty could not be resolved externally.
“that uncertainty either couldn't be resolved because it was in the heads of one or two people at Treasury.”
Open the episode · E417: $20B Investor on Risk, Uncertainty & AdaptabilityListen at 6:49
Cramer recommends buying AbbVie.
“I want you to buy it.”
Open the episode · Mad Money w/ Jim Cramer 7/15/26Listen at 7:50
AbbVie shares are rising nearly 1% premarket.
“Abbvie shares are actually up about nearly 1% in the pre market.”
Open the episode · Arcosa and Apogee Rise; Getty JumpsListen at 2:12
AbbVie lost $24 billion in market capitalization after J&J approval
“AbbVie, here it is, lost $24 billion worth of market capitalization on the approval of the J&J drug.”
Open the episode · Mad Money w/ Jim Cramer 3/19/26Listen at 22:31
AbbVie’s stock will reach $250.
“I think it goes to 250.”
Open the episode · Mad Money w/ Jim Cramer 10/24/25Listen at 31:26
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.